AAPP Scientific Poster Session Abstracts

5-HT2C Receptors Contribute to Viloxazine’s Effects on ADHD-relevant Behaviors in Rats on the 5-Choice Serial Reaction Time Task ADHD

A Convergent, Parallel, Mixed Methods Study to Identify Barriers to Access to Mental Health Care in the Haitian Population of a Midwestern Academic Medical Center Health Equity Immigrant And Minority Health

A Prescription Digital Therapeutic, CT-152, for Treating Major Depressive Disorder: Effectiveness and Safety Results of the MIRAI Randomized Controlled Trial Depression

A Randomized, Open Label, Multiple-dose, Two-way Study to Evaluate Bioavailability of Clonidine HCl Extended-release Oral Suspension compared to Clonidine HCl Extended-release Tablets Child And Adolescent Psychiatry ADHD Non-Stimulant

A Retrospective Comparison of Initiation with Intramuscular Paliperidone Palmitate LAI and Subcutaneous Risperidone LAI on 30-day Readmission Rates in a Behavioral Health Inpatient Treatment Facility Adherence Antipsychotics Bipolar Disorder Education/Training/Stigma Long-Acting Injectable Schizophrenia Transitions Of Care Mood Stabilizers Risperidone Paliperidone Readmission Rate

A Retrospective Evaluation of Benzodiazepine Tapering Practices and Outcomes in Veterans Following Chronic Use at a Level 1A Federal Healthcare System Anxiolytics Harm Reduction Schizophrenia VA Benzodiazepine

A Retrospective Review of As-Needed Medications and Their Role in Predicting Aggression in Forensic Psychiatric Patients Antipsychotics Harm Reduction Aggression Forensic Pro Re Nata

A Review of the Delivery Technologies used in Attention-Deficit/Hyperactivity Disorder Stimulant Medications Child And Adolescent Psychiatry Education/Training/Stigma Stimulants

Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From an Additional Randomized, Double-Blind, Phase 3 Trial Antipsychotics Major Depression Lumateperone

Advancing Schizophrenia Treatment: A Modified Delphi Consensus on The Critical Role of Psychiatric Pharmacists in Prescription Digital Therapeutics Schizophrenia Delphi Consensus Digital Therapeutics Psychiatric Pharmacist

Alternative Modes of Administration for Once-Daily Valbenazine to Treat Tardive Dyskinesia or Chorea Associated With Huntington’s Disease in Patients Experiencing Dysphagia Antipsychotics Bipolar Disorder Neurology Schizophrenia Suicide Tardive Dyskinesia

An Evaluation of Buprenorphine Transition Strategies in a Pharmacist-Led Chronic Pain Clinic Health Equity VA Buprenorphine Pain Management

Analysis of Correlation Between Total Anticholinergic Load and As-Needed Medication Administrations in an Inpatient Psychiatric Hospital Acute Agitation Antipsychotics Drug-Drug Interactions Geriatrics Harm Reduction Monitoring Schizophrenia Therapeutic Drug Monitoring

Antimicrobial Exposure and Risk for Major Depressive Disorder Recurrence Antidepressants Major Depression VA Antibacterial

Antipsychotic Prescribing Patterns in Dual Diagnosis Patients on ED Discharge Acute Agitation Alcohol Use Disorder Antipsychotics Education/Training/Stigma Substance Use Disorders Transitions Of Care

Appropriateness of Antipsychotic Long Acting Injectable (LAI) Prescribing, Monitoring, and Administration at VA Northern California Health Care System (VANCHCS) Antipsychotics Bipolar Disorder Geriatrics Long-Acting Injectable Schizophrenia

Aripiprazole Levels After Inadvertent Administration of Aripiprazole lauroxil 1064 mg in the Deltoid Muscle: a case report Long-Acting Injectable Therapeutic Drug Monitoring Aripiprazole Lauroxil Pharmacokinetics

Aripiprazole, A Partial Dopamine Agonist Antipsychotic, and Its Effects on Psychosis When Used Concomitantly with Full Dopamine Antagonist Antipsychotics Acute Agitation Antipsychotics Bipolar Disorder Schizophrenia Psychosis

As-Needed Medication Use for Agitation and Psychosis Across Valproic Acid Formulations Acute Agitation Antipsychotics Bipolar Disorder Mood Stabilizers

Assessing the Impact of Naloxone Training for Students, Faculty, and Staff within a School of Pharmacy Education/Training/Stigma Harm Reduction Opioid Use Disorder Substance Use Disorders

Assessing the Impact of Patient Health Questionnaire-9 and General Anxiety Disorder-7 Monitoring in Outpatient Depression and Anxiety Antidepressants Major Depression Monitoring VA Generalized Anxiety Disorder GAD-7 Patient Health Questionnaire PHQ-9

Assessing the Pharmacist's Role in Harm Reduction via Clinical Exposure Alcohol Use Disorder Harm Reduction Opioid Use Disorder Substance Use Disorders

Attitudes Towards Pharmacy Amongst Those That Actively Inject Drugs Alcohol Use Disorder Harm Reduction Opioid Use Disorder Substance Use Disorders

Atypical Antipsychotic Associated Weight Gain for Autism Spectrum Disorder Irritability Antipsychotics Child And Adolescent Psychiatry

Awareness and Perceptions of Fentanyl Criminalization Policies: A Survey Report Education/Training/Stigma Harm Reduction Health Equity Opioid Use Disorder Substance Use Disorders

Barriers to Utilization of Clozapine versus Antipsychotic Polypharmacy in a State Hospital System Antipsychotics Schizophrenia Polypharmacy

Budget Impact analysis of Xanomeline and Trospium Chloride for the Treatment of Adults with Schizophrenia in the US Antipsychotics Schizophrenia Budget Impact Analysis Muscarinic Receptors

Buspirone Use Evaluation at an Inpatient Psychiatric Hospital Adherence Antidepressants Antipsychotics Anxiolytics Harm Reduction Major Depression

Characterization of Medications Prescribed for Agitation in a Psychiatric ICU Acute Agitation Antipsychotics Anxiolytics

Clinical Outcomes of Long-Acting Injectables in People Experiencing Homelessness Adherence Antipsychotics Long-Acting Injectable Schizophrenia Substance Use Disorders Homelessness

Clozapine Continuity: The Key to Stability Amid Command Hallucinations and Detrimental Self-Injury Acute Agitation Adherence Antipsychotics Education/Training/Stigma Harm Reduction Long-Acting Injectable Monitoring Schizophrenia Therapeutic Drug Monitoring Treatment Barriers REMS Program Self-Injurious Behavior

Clozapine-Induced Eosinopenia in Patients with Treatment-Resistant Schizophrenia: Case Series and Literature Review Antipsychotics Schizophrenia Side Effects Eosinopenia Clozapine

Cobalamin Conundrum: How low can B12 go? Geriatrics Monitoring Neurology Substance Use Disorders B12 Deficiency

Commercially Insured Patient Profiles and Risk Factors Attributing to Non-Adherence Amongst Opioid Use Disorder Patients (OUD) Treated with Monthly Injectable Buprenorphine: A Retrospective Claims Analysis Adherence Alcohol Use Disorder Antidepressants Antipsychotics Long-Acting Injectable Major Depression Opioid Use Disorder Stimulants Substance Use Disorders

Community Pharmacy-Based Long-Acting Injectable (LAI) Service Reimbursement Adherence Antipsychotics Education/Training/Stigma Long-Acting Injectable Monitoring Opioid Use Disorder Schizophrenia Substance Use Disorders

Comparison of High-Dose Olanzapine and Standard-Dose Olanzapine in Adult Patients at a County Psychiatric Hospital (A Continuation Study) Antipsychotics Schizophrenia Olanzapine Readmission Rates

Compatibility of Administering Long-Acting Injectable Antipsychotics in Community Pharmacies across Washington State Antipsychotics Long-Acting Injectable Health Services

Continuing Professional Development Self-Reporting by Board-Certified Psychiatric Pharmacists Education/Training/Stigma Board Certification Continuing Professional Development

CT-152, a Prescription Digital Therapeutic for Major Depressive Disorder: A Real-World Analysis of Durability of Treatment Effect Depression

Describing Intravenous Ketamine Response for Treatment-Resistant Depression or Major Depressive Disorder with Suicidal Ideation in Intranasal Esketamine Non-Responders Antidepressants Major Depression Suicide VA

Determining the Average Anticholinergic Burden in Inpatient Psychiatric Patients Across Various Age Groups Antidepressants Antipsychotics Bipolar Disorder Drug-Drug Interactions Geriatrics Major Depression Schizophrenia

Development of a Pharmacist-Led Pediatric Long-Acting Injectable Antipsychotic (LAI-A) Treatment Program Antipsychotics Child And Adolescent Psychiatry Long-Acting Injectable

Development of a Scoring Tool to Identify High-Risk Discharges in Psychiatric Transitions of Care Adherence Antipsychotics Long-Acting Injectable Therapeutic Drug Monitoring Transitions Of Care

Early Improvement of Symptoms in Bipolar I Depression Predicts Functional Response and Recovery: A Post Hoc Analysis Antidepressants Bipolar Disorder Major Depression Neurology

Education on Proper Administration of Transmucosal Buprenorphine to Improve Dental Adverse Outcomes in Patients with OUD Adherence Education/Training/Stigma Health Equity Opioid Use Disorder Substance Use Disorders

Effect of Antipsychotic Initiation on Psychotic Symptoms in Patients Using Stimulants: A Retrospective Chart Review Antipsychotics Stimulants Substance Use Disorders Methamphetamine-Induced Psychosis

Effectiveness of Pharm.D.-Integrated Mental Health Courses for Improving Perceptions of Mental Health Conditions Among Pharmacy Students Education/Training/Stigma Mental Health First Aid

Effects of Injectable Calcitonin Gene Related Peptide-Antagonists on Migraine-Associated Cost Burden Long-Acting Injectable Neurology VA Migraine Headache Headache

Efficacy and Safety of Esketamine Nasal Spray as Monotherapy in Adult Patients with Treatment-Resistant Depression for up to 4-Months of Treatment: A Post Hoc Analysis Antidepressants Major Depression Treatment-Resistant Depression Esketamine

Efficacy of Mirtazapine Versus Clonidine for Resistant PTSD Nightmares in Veterans: An Observational Study Post-Traumatic Stress Disorder/ PTSD VA

Enhancing Clinical Vigilance: Utilizing the Simpson-Angus Scale in Provider Trainings for Detection of Parkinsonian Symptoms in Antipsychotic Treatment in Outpatient Mental Health Settings Antipsychotics Education/Training/Stigma Simpson Angus Scale Parkinsonian Symptoms

Enhancing Naloxone Distribution and Education to At-Risk Veterans Through Utilization of AudioCARE Technology Harm Reduction Opioid Use Disorder Stimulants Substance Use Disorders VA Stimulant Use Disorder

Establishing and Evaluating a Clinical Pharmacist’s Role in an Outpatient Geropsychiatry Clinic Education/Training/Stigma Geriatrics Monitoring Stimulants VA Interprofessional Collaboration

Evaluating A Pharmacist Driven Clozapine Best Practices Standardization in Inpatient Psychiatry Units Antipsychotics Schizophrenia Clozapine

Evaluating Concurrent Benzodiazepine and Opioid Use after an Educational Intervention in Eligible Veterans at a Veterans Affair Outpatient Health Care System Drug-Drug Interactions Harm Reduction VA

Evaluating the Administration of One-time Order Intramuscular Antipsychotics Amongst Different Racial Groups Within Adult Inpatient Psychiatric Units Acute Agitation Antipsychotics Education/Training/Stigma Health Equity

Evaluating the Effectiveness and Safety of Cariprazine on Inpatient Psychiatry: A Medication Use Review Antipsychotics Bipolar Disorder Major Depression Schizophrenia

Evaluating the Effects of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on Substance Use Disorders Alcohol Use Disorder Substance Use Disorders Nicotine Dependence/use Disorder/tobacco Dependence/use Disorder Cocaine Use Disorder Glucagon-Like Peptide-1 Receptor Agonist

Evaluating the Perceived Value of Psychiatric Clinical Pharmacist Specialist Services Education/Training/Stigma Multidisciplinary Healthcare Teams Cost Avoidance Analysis Surveys And Questionnaires Attitude Of Health Personnel

Evaluating the Transition from Full Agonist Opioid to Buprenorphine for Management of Veterans on Long Term Opioid Therapy for Chronic Pain Harm Reduction VA Pain Opioids

Evaluating the Understandability, Actionability, Quality, and Readability of AI-Generated Health Information on Eating Disorders: A Comparative Analysis of ChatGPT Free and Pro Versions Education/Training/Stigma Artificial Intelligence Chat-GPT Eating Disorders Health Literacy

Evaluating the Use of Sexually Transmitted Infection Testing in a Psychiatric Hospital Health Equity Monitoring Sexually Transmitted Infections Public Health

Evaluating the Utility of a Retrospective, Pharmacy-Initiated Medication Reconciliation Process Transitions Of Care Medication Reconciliation

Evaluation and Optimization of Medication Management to Prevent Restraint Episodes in Adult Patients Admitted to an Inpatient Psychiatric Facility Acute Agitation Antipsychotics Anxiolytics Harm Reduction Suicide Therapeutic Drug Monitoring Mood Stabilizers Physical Restraint

Evaluation and Reduction of Pill Burden in the Inpatient Psychiatric Setting Acute Agitation Adherence Harm Reduction

Evaluation of Midazolam Efficacy as an Alternative for Lorazepam for Management of Acute Agitation in Behavioral Health Patients Acute Agitation Anxiolytics Benzodiazepine

Evaluation of Naloxone Kits Prescribed to Patients Diagnosed With Stimulant Use Disorder Education/Training/Stigma Harm Reduction Substance Use Disorders VA

Evaluation of Paliperidone Palmitate Loading Doses in Adult Patients with Reduced versus Normal Renal Function at a Stand-Alone Psychiatric Hospital Antipsychotics Long-Acting Injectable

Evaluation of Patient Outcomes Associated with Administration of Long-Acting Injectable Antipsychotics in the Inpatient Psychiatric Setting Antipsychotics Bipolar Disorder Long-Acting Injectable Schizophrenia Therapeutic Drug Monitoring

Evaluation of Pharmacy Means Reduction for Veterans Enrolled in the High Risk for Suicide Program Adherence Harm Reduction Suicide Transitions Of Care VA

Evaluation of Psychiatric Pharmacists’ Perspectives of Medical and Recreational Cannabis Education/Training/Stigma Substance Use Disorders Cannabis

Evaluation of the Appropriateness of Haloperidol Decanoate Dosing in Inpatients with Serious Mental Illness Antipsychotics Long-Acting Injectable Schizophrenia Therapeutic Drug Monitoring

Evaluation of the Distribution of Naloxone Kits in Patients Diagnosed with Opioid Use Disorder Harm Reduction Opioid Use Disorder Substance Use Disorders VA

Evaluation of the Feasibility and Potential Impact of Providing Ambulatory Alcohol Withdrawal Management Within A VA Medical Center Alcohol Use Disorder Opioid Use Disorder VA Alcohol Withdrawal Ambulatory Care Healthcare Cost Savings

Evaluation of the Utilization of Pharmacological Treatment for Alcohol Use Disorder in an At-Risk Outpatient Veteran Population Alcohol Use Disorder Harm Reduction Substance Use Disorders VA

Evaluation of Therapeutic Indication and Utilization of Lamotrigine in an Inpatient Psychiatric Hospital Adherence Bipolar Disorder Education/Training/Stigma Transitions Of Care Mood Stabilizers Dosing/Titration Practices

Exploring Mental Health Service Utilization and Challenges Among Graduate Students in Healthcare Programs: A Cross-Sectional Study Education/Training/Stigma Health Equity

Factors Associated With Delta-8 Tetrahydrocannabinol Admission To A Behavioral Health Hospital Substance Use Disorders Cannabis

Factors Influencing Hospital Length of Stay in Patients Receiving New Lithium Therapy for Acute Bipolar Illness at an Inpatient Psychiatric Facility Bipolar Disorder Therapeutic Drug Monitoring Mood Stabilizers

Identification and Assessment of Mental Health-Related Stigma in Relation to Mental Health Diagnosis and Medication Use Among College Students Education/Training/Stigma Transitions Of Care Mental Health

Impact of a Board-Certified Psychiatric Pharmacist Integrated into a Team-Based Outpatient Psychiatry Clinic Antidepressants Major Depression Ambulatory Care Collaborative Practice

Impact of a Mental Health Clinical Pharmacist Practitioner on Patient Outcomes at a Veterans Substance Abuse Treatment Team Clinic Alcohol Use Disorder Substance Use Disorders VA

Impact of a Pharmacy Mental Health Practitioner on an Inpatient Psychiatry Consultation Liaison Service Impact Consultation Liaison Mental Health Clinical Pharmacy Practitioner

Impact of a Text Message Intervention on Naloxone Prescriptions for Individuals with Stimulant Use Disorder Harm Reduction Stimulant Use Disorder

Impact of Ambulatory Care Psychiatry Pharmacist Medication Reviews and Histories Adherence Bipolar Disorder Drug-Drug Interactions Major Depression Schizophrenia Ambulatory Care

Impact of Esketamine Therapy Discontinuation on Depression Stability in Veterans with Treatment Resistant Depression Antidepressants Major Depression VA Treatment-Resistant Depression/ Treatment Refractory Depression Esketamine

Impact of Inpatient Pharmacist-Led Metabolic Monitoring in Patients Administered Antipsychotics Antipsychotics Monitoring

Impact of Patient Demographics on Prescribing Practices on an Inpatient Child and Adolescent Psychiatric Unit Antipsychotics Child And Adolescent Psychiatry Health Equity Stimulants Mood Stabilizers

Impact of Patient Variables and Time of Day on Clozapine Serum Concentrations Using a Novel Immunoassay Platform Antipsychotics Schizophrenia

Impact of Pharmacist Clinical Monitoring of Lithium in an Inpatient Psychiatric Setting Bipolar Disorder Drug-Drug Interactions Monitoring Therapeutic Drug Monitoring Mood Stabilizers

Impact of Psychiatry Advanced Pharmacy Practice Experience on Student Pharmacist Apprehensions Towards Psychiatry Education/Training/Stigma Students Engagement

Impact of Social Determinants of Health on Escalation to Antipsychotic Polypharmacy in Outpatient Mental Health Clinics Antipsychotics Education/Training/Stigma Health Equity Schizophrenia VA Social Determinants Of Health

Impact of the Integration of a Clinical Pharmacy Specialist into a Ketamine Infusion Clinic for Treatment-Resistant Depression Antidepressants Major Depression

Implementation and Evaluation of Pharmacist-Led Pharmacogenomic Testing for Antidepressant Therapy in Patients with Treatment Resistant Depression at a Single-Center Veteran Affairs Hospital Adherence Antidepressants Major Depression Pharmacogenomics VA

Implementation of a Pharmacist Led Clinic in Outpatient Mental Health Monitoring Therapeutic Drug Monitoring VA

Implementation of a Syringe Services Program (SSP) at a Rural Veterans Affairs Medical Center and Outpatient Clinics: A Harm Reduction Project Harm Reduction Substance Use Disorders

Implementing Esketamine: A Pilot Study for Enhancing Treatment-Resistant Depression Care in a Health System Antidepressants Major Depression Esketamine Treatment-Resistant Depression Practice Innovation

Improving Access to Naloxone for Patients with Stimulant Use Disorder Education/Training/Stigma Stimulants VA Harm Reduction

Improving Laboratory Monitoring Compliance in Patients Prescribed Antipsychotics, Lithium, or Divalproex Sodium with Pharmacist-Led Intervention Antipsychotics Harm Reduction Monitoring Therapeutic Drug Monitoring Mood Stabilizers Laboratory

Improving SUD Harm Reduction Efforts in Community Pharmacies via an Asynchronous Education Program Education/Training/Stigma Harm Reduction Health Equity Opioid Use Disorder Substance Use Disorders

Increasing Access to Pharmacogenomics Testing to Veterans with Mental Health Disorders Health Equity Monitoring Pharmacogenomics VA

Integration of a Psychiatric Pharmacist into a Pediatric Psychiatric Emergency Department and Novel Outpatient Crisis Clinic Child And Adolescent Psychiatry BCPP Integration Mental Health Crisis

Integration of Mental Health Clinical Pharmacist Practitioner into Inpatient Substance Use Disorder Consult Team to Expand Substance Use Disorder Pharmacotherapy Initiation for Hospitalized Patients Alcohol Use Disorder Health Equity Opioid Use Disorder Substance Use Disorders Transitions Of Care VA

Investigating the trends in novel designer drug use in Los Angeles County from 2020-2023 Harm Reduction Substance Use Disorders Designer Drug

Long-term Dexamethasone in the Treatment of Secondary Epilepsy due to Grade 4 Astrocytoma IDH Mutant Neurology Brain Neoplasm

Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: Results from the 52-Week, Open-Label EMERGENT-4 Trial Antipsychotics Schizophrenia Muscarinic Receptors Xanomeline Trospium

Long-Term Safety, Tolerability, and Efficacy of Xanomeline and Trospium Chloride in People With Schizophrenia: Results From the 52-Week, Open-Label EMERGENT-5 Trial Antipsychotics Schizophrenia Muscarinic Receptors Xanomeline Trospium

Louisiana Community Pharmacist Knowledge and Attitudes Toward Medication-Assisted Treatment (MAT) for Opioid Use Disorder: A Qualitative Study Harm Reduction Opioid Use Disorder Substance Use Disorders

Low-Dose Glucagon-Like Peptide-1 Receptor Agonists to Reverse Antipsychotic-Induced Weight Gain in Patients with Type 2 Diabetes Mellitus Antipsychotics Monitoring Schizophrenia Diabetes

Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial Antipsychotics Major Depression Lumateperone

Medication Adherence Following Pharmacogenomic Testing in Insurance Claims Data from Patients with Major Depressive Disorder Adherence Antidepressants Major Depression Pharmacogenomics

Medication Superhero Group on an Inpatient Child Psychiatry Unit Adherence Child And Adolescent Psychiatry Education/Training/Stigma Post-Traumatic Stress Disorder/ PTSD ADHD

Monitoring Pharmacogenomic Interventions in the Mental Health Setting at a Veterans Affairs Hospital Pharmacogenomics VA

Nonprescription Syringe and Over-the-Counter Naloxone Availability in Community Pharmacies: A Secret Shopper Purchase Audit in Austin, TX Education/Training/Stigma Harm Reduction Health Equity Opioid Use Disorder Substance Use Disorders

Not just a weight loss drug-Exploring the Potential of GLP-1 Receptor Agonists in Treating Substance Use Disorders Alcohol Use Disorder Opioid Use Disorder Substance Use Disorders

Opioid Use Disorder Medicaid Patient Profiles and Risk Factors Contributing to Non-Adherence to Monthly Injectable Buprenorphine: Retrospective Claims Analysis Adherence Alcohol Use Disorder Antidepressants Antipsychotics Long-Acting Injectable Opioid Use Disorder Stimulants Substance Use Disorders

Optimizing Management of Opioid-Induced Constipation at a Single Veterans Affairs Medical Center Monitoring Opioid Use Disorder Pain Management

Optimizing Medication Services for the Unhoused in a Street Psychiatry Clinic VA Street Psychiatry

Optimizing Pharmacotherapy for Suicidal Ideation: An Evaluation of Appropriate Initiation Strategies at a Large Non-Profit Hospital Major Depression Suicide

Outcomes of a Pharmacist-Led Benzodiazepine Taper Clinic Anxiolytics Substance Use Disorders Therapeutic Drug Monitoring VA Benzodiazepine

Outcomes Related to Psychiatric Pharmacist Care of Patients with Mental Illness Harm Reduction Monitoring Therapeutic Drug Monitoring Transitions Of Care VA

Outpatient Long-Acting Injectable Antipsychotic Clinic in a Safety Net Hospital Adherence Antipsychotics Bipolar Disorder Long-Acting Injectable Schizophrenia

Patient and Environmental Factors Affecting Sublingual Buprenorphine Prescription Pick-up Health Equity Opioid Use Disorder Substance Use Disorders Pharmacy Access

Patient Characteristics Associated with Medication Selection for Acute Agitation in a Behavioral Health Emergency Department Acute Agitation Health Equity

Patients and Providers Satisfaction Surveys on Long-Acting Injection Antipsychotics Adherence Antipsychotics Long-Acting Injectable

Patients' Preferences Towards Antipsychotic Induced Weight Gain Management Antipsychotics Antipsychotic-Induced Weight Gain

Patterns of Pharmacologic Treatment for the Inpatient Management of Acute Bipolar Depression Antidepressants Antipsychotics Bipolar Disorder Mood Stabilizers

Perceptions of Psychiatric Care Amongst Formerly Incarcerated Individuals Education/Training/Stigma Health Equity Transitions Of Care Mood Stabilizers Incarcerated Populations

Pharmacist-Led Education and Training of Health Care Practitioners to Administer Long-Acting Injectable Medications Antipsychotics Bipolar Disorder Long-Acting Injectable Schizophrenia

Pharmacist-led Implementation of Extended-release Buprenorphine in an Inpatient General Psychiatry Unit Antipsychotics Bipolar Disorder Long-Acting Injectable Opioid Use Disorder Schizophrenia Substance Use Disorders Buprenorphine

Pharmacist-Led Psychotropic Stewardship Program to Assess Antipsychotic Polypharmacy Adherence Antipsychotics Bipolar Disorder Child And Adolescent Psychiatry Long-Acting Injectable Schizophrenia Antipsychotic Polypharmacy Psychotropic Stewardship Medication Management Extrapyramidal Side Effects Inpatient Psychiatry

Pharmacy-Led Medication Reconciliation at an Inpatient Behavioral Health Facility Transitions Of Care Medication Reconciliation

Phenobarbital Versus Benzodiazepine for Alcohol Withdrawal in General Medicine Setting: Focus on Safety and Hospital Length of Stay Alcohol Use Disorder VA Alcohol Withdrawal Benzodiazepine Phenobarbital

Postoperative Buprenorphine Management in Patients Taking Buprenorphine Prior to Admission Opioid Use Disorder Pain

Potential Inpatient Cost-Savings Using Subcutaneous Risperidone ER Versus Paliperidone Palmitate Based on Prescribing Trends of Oral Risperidone Adherence Antipsychotics Health Equity Long-Acting Injectable Schizophrenia Transitions Of Care Pharmacoeconomics Formulary Management

Prevalence of ADHD in People Who Use Methamphetamine Harm Reduction Stimulants Substance Use Disorders ADHD Methamphetamine

Provider Perspectives on Low-Dose Initiation Strategies for Buprenorphine Substance Use Disorders Microdosing Fentanyl Precipitated Withdrawal

Psilocybin for Treatment Resistant Depression: Exploring Potential Mechanisms of Action and Addressing Unblinding in Randomized Control Trials Antidepressants Major Depression Psilocybin Treatment-Resistant Depression

Psychedelic-Assisted Therapy for PTSD and Depression: a review of the literature Antipsychotics Neurology Post-Traumatic Stress Disorder/ PTSD Stimulants Controlled Substances MDMA

Psychiatric Electives in United States Colleges of Pharmacy: A Narrative Review Education/Training/Stigma Pharmacy Curriculum Educational Gaps

Psychiatric Pharmacist consultation orders in a Pediatric Mental Health Institute Child And Adolescent Psychiatry Drug-Drug Interactions Monitoring

Psychiatric Pharmacist Impact on Long-Acting Injectable Antipsychotic Utilization Antipsychotics Long-Acting Injectable Advancing Pharmacy Practice

Psycho-Oncology and the Use of Psychotropics for the Management of Chemobrain Symptoms: A Review of the Literature Antidepressants Oncology Chemotherapy Cognitive Impairment Psycho-Oncology

Quality, Readability, Accessibility, and Understandability of Chat GPT-Generated Information for Alzheimer's Disease Education/Training/Stigma Artificial Intelligence Alzheimer's Disease

Quantifying Nonprescription Syringe Access in Oregon: A County-Level Perspective Harm Reduction Health Equity Substance Use Disorders

Recurrent Clozapine Induced Pneumonia  Antipsychotics Schizophrenia

Reimplementation of a Pharmacist-Centered Contingency Management Service – Current Challenges and Expansions to the Program Substance Use Disorders VA

Relationship Between Patient-specific Factors and Clozapine Prescribing During Psychiatric Hospitalization Antipsychotics Monitoring Schizophrenia Therapeutic Drug Monitoring Clozapine

Retrospective Review of Hospital Length of Stay in Patients Receiving As-Needed Olanzapine After Implementation of As Needed (PRN) Agitation Order Set Antipsychotics Transitions Of Care VA

Retrospective Study of Neuropsychiatric Hospitalizations in Patients Receiving Montelukast vs. Loratadine for Allergic Rhinitis in a Veterans Affairs Population Harm Reduction Major Depression Monitoring Suicide VA Adverse Drug Events Hospitalization Black Box Warning

Safety and Tolerability of Lumateperone 42 mg for the Adjunctive Treatment of Major Depressive Disorder: A Pooled Analysis of 2 Randomized Placebo-Controlled Trials Antipsychotics Major Depression Lumateperone

Serotonin Syndrome and Protracted Discontinuation Syndrome with Escitalopram in a CYP2C19 Poor Metabolizer – A case report Antidepressants Anxiolytics Pharmacogenomics

Somatic Symptom Disorder: Role of the Pharmacist in Minimizing Polypharmacy Antipsychotics Geriatrics Harm Reduction Transitions Of Care

Strengthening the Behavioral and Mental Health Workforce Through Pharmacy Education Education/Training/Stigma Health Policy Postgraduate Training

Study Retention Rates in the Olanzapine/Samidorphan Phase 3 Clinical Program Adherence Antipsychotics Schizophrenia Olanzapine Bipolar I Disorder Retention Samidorphan

Sublingual Dexmedetomidine versus Standard of Care for Agitation within an Inpatient Psychiatric Facility Acute Agitation Antipsychotics Bipolar Disorder Schizophrenia

Substantial Long-Term Improvements With Valbenazine 40 mg in Adults with Tardive Dyskinesia Antipsychotics Bipolar Disorder Neurology Schizophrenia Tardive Dyskinesia

Survey of Local Patterns of Fentanyl Exposure and Assessment of Harm Reduction Strategies Harm Reduction Opioid Use Disorder Substance Use Disorders

Systematic Review of Montelukast’s Potential for Drug Repurposing and Management of Neurodegenerative Disorders Neurology Montelukast Neurodegenerative Disease/disorder

Texas Community Pharmacists’ Knowledge, Perceptions, and Practices Related to Dispensing Buprenorphine for Opioid Use Disorder: A Cross-Sectional Online Survey Education/Training/Stigma Harm Reduction Health Equity Opioid Use Disorder Substance Use Disorders

The Association Between Mental Health Disorders and Allergic Reactions: A Multicenter Retrospective Analysis Mental Disorders Allergy/allergies Hypersensitivity

The Effect of Subcutaneous Risperidone Long-Acting Injectable on 30-Day Readmission Rates in Adult and Adolescent Patients at a Safety-Net Psychiatric Hospital: a Retrospective Review Antipsychotics Child And Adolescent Psychiatry Long-Acting Injectable

The Impact of a Modified Clozapine Titration Protocol on the Rates of Diagnosed Clozapine-Induced Myocarditis for Newly Initiated Patients Admitted to a Stand-Alone Psychiatric Hospital Antipsychotics Monitoring Clozapine

The Impact of Antipsychotics in the Treatment of Catatonia Antipsychotics Catatonia

The impact of initiating pharmacotherapy for alcohol use disorder in the inpatient medical unit on hospital readmission rates for alcohol withdrawal at a Federal Health Care Center Alcohol Use Disorder Education/Training/Stigma VA

The Impact of Pharmacogenomic Testing on Antidepressant Therapy at a VA Medical Center Antidepressants Pharmacogenomics VA

The Occurrence of Mental Health Diagnoses in GLP-1 Receptor Agonist Treated Patients Monitoring Suicide

The Pharmacist's Role in Clozapine Initiation: Early Detection of Clozapine-Induced Myocarditis – A Case Report Antipsychotics Monitoring Clozapine Pharmacist-Led Protocol

The Role of the Psychiatric Pharmacist in Shared Medical Appointments for Individuals with Bipolar Disorder Bipolar Disorder Shared Medical Appointments

Therapeutic Use of Cannabidiol (CBD) in Autism Spectrum Disorder: A Comprehensive Review of Mechanisms of Action and Clinical Applications Child And Adolescent Psychiatry Drug-Drug Interactions Autism Spectrum Disorder Cannabinoids Cannabidiol

Tirzepatide-The first and only prescription medicine for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity: A Scoping Review Sleep Disorder GLP-1

Transitioning Patients to Longer Duration Long-Acting-Injectable Antipsychotics at a Certified Community Behavioral Health Clinic Adherence Antipsychotics Long-Acting Injectable

Treatment Patterns and Healthcare Resource Utilization of Patients With Schizophrenia Prescribed Aripiprazole Lauroxil Versus Oral Aripiprazole: A Retrospective Claims-Based Study Adherence Antipsychotics Long-Acting Injectable Schizophrenia Atypical Antipsychotic Healthcare Resource Utilization Treatment Patterns

Use of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) on Alcohol Use Disorder and Opioid Use Disorder Healthcare Related Outcomes Alcohol Use Disorder Opioid Use Disorder Substance Use Disorders VA

Use of Hypnotic Agents for Pediatric/Adolescent Patients in an Inpatient Behavioral Health Facility Child And Adolescent Psychiatry Hypnotics Insomnia

Use of Vilazodone for the Treatment of Posttraumatic Stress Disorder Antidepressants Post-Traumatic Stress Disorder/ PTSD

Utilizing Pharmacist Roles to Improve the Use of Medication Assisted Therapy for Alcohol Use Disorder on an Internal Medicine Floor at a VA Institution Alcohol Use Disorder Substance Use Disorders VA

Utilizing Pharmacogenomic Testing Among Primary Care Providers to Guide Initial Antidepressant Therapy Selection Antidepressants Major Depression Pharmacogenomics VA

Utilizing Vaccine Outreach to Assess Day Center Client Mental Health: A Single-Center, Prospective Study Alcohol Use Disorder Harm Reduction Opioid Use Disorder Substance Use Disorders Transitions Of Care

Viloxazine Extended-release Capsules Meaningfully Improved Executive Function in Adult ADHD: Post-Hoc Analyses of Phase III Double-Blind and Open-Label Extension Trials ADHD Nonstimulant Cognition Executive Function

Weight loss was more common than weight gain in Adults treated with Viloxazine ER for Attention-Deficit/Hyperactivity Disorder in short and long-term phase 3 clinical trials ADHD Nonstimulants